Genmab, BioNTech Join Forces For Cancer Immunotherapy Candidates

Genmab A/S GMAB and BioNTech SE BNTX have expanded their global strategic collaboration to develop and commercialize novel cancer immunotherapies.
Under the expansion, Genmab and BioNTech will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications.
The expanded collaboration will leverage Genmab's HexaBody technology platform.
The first monospecific antibody candidate, GEN1053/BNT313, is expected to enter clinical trials by the end of 2022.
The companies will equally share the development costs and potential future profit from GEN1053/BNT313.
Since 2015, the companies have been working on the joint development of bispecific cancer antibodies.
The companies currently have two jointly developed investigational medicines in clinical testing since 2019, including:
- GEN1046/BNT311 in phase 1/2 trials for advanced solid tumors and a phase 2 study for non-small cell lung cancer.
- GEN1042/BNT312 in Phase 1/2 study for metastatic or locally advanced solid tumors.
Price Action: GMAB stock is down 2.72% at $35.03 on the last check Friday.